搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
生物谷
17 天
Cell重磅:颠覆对核糖体的认知!癌细胞通过劫持核糖体以逃逸免疫系统
研究团队发现,当细胞收到来自免疫系统的危险信号时,它们的核糖体会发生改变。炎性细胞因子改变了一种核糖体的平衡,这种核糖体有一个灵活的“臂”伸出来,叫做P-stalk,从而更好地向免疫系统展示自己。P-stalk是个向外延伸的五聚体臂,由两个P1蛋白和 ...
腾讯网
7 天
癌细胞的隐形斗篷——核糖体?Cell:癌细胞竟可利用核糖体逃避免疫 ...
想象一下,我们的身体里有一百万个微小的蛋白工厂,它们就是核糖体。这些工厂负责制造我们身体所需的所有蛋白质。长期以来,科学家们认为所有的核糖体都是一样的,只是按照指令机械地工作。然而,一项新的研究改变了这一看法,揭示了核糖体的多样化功能,尤其是它们在帮 ...
2 天
Werewolf Therapeutics Advances Innovative Cytokine Therapies
Werewolf Therapeutics ( (HOWL) ) just unveiled an update. Werewolf Therapeutics is pioneering the development of innovative cytokine therapies ...
Nature
3 年
Cytokine networks—towards new therapies for rheumatoid arthritis
As therapeutic goals move from disease control towards remission induction, development of the capacity for cytokine targeting to modify the underlying immune dysregulation remains a major priority.
20 天
肿瘤完全清除超过40个月!《NEJM》:手术前后都用免疫治疗,抗癌 ...
为了提高抗肿瘤的疗效,该患者采用了交替输注CIK细胞和NK细胞的治疗方案,并取得了良好的结果。患者 已处于NED状态40个月 ,并将继续保持该状态。NED就是无疾病状态(No Evidence of ...
PharmTech
24 分钟
Behind the Headlines: What the US Election Results Mean for Industry, In Vivo CAR-T ...
Brian Feth and Jonathan Grinstein go behind the headlines to discuss the impact of a Republican administration on Federal ...
4 小时
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell ...
Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of ...
FierceBiotech
1 天
Adaptimmune gears up for another FDA submission after hitting goal in pivotal sarcoma study
All patients experienced treatment-emergent adverse events, Adaptimmune said. The most common adverse events were cytopenias, ...
Yahoo Finance
10 小时
Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints
In synovial sarcoma, the median response lasted for 18.3 months, while in MRCLS, the median response was 12.2 months. All ...
1 天
Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on ...
Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in late Q1/early Q2 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈